SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $482,000 | -13.8% | 18,080 | -0.3% | 0.01% | -15.4% |
| Q2 2021 | $559,000 | +17.9% | 18,140 | +0.2% | 0.01% | +8.3% |
| Q1 2021 | $474,000 | +13.9% | 18,100 | +9.6% | 0.01% | +9.1% |
| Q4 2020 | $416,000 | +20.9% | 16,520 | +31.8% | 0.01% | +10.0% |
| Q3 2019 | $344,000 | -18.1% | 12,530 | -1.3% | 0.01% | -16.7% |
| Q2 2019 | $420,000 | -11.9% | 12,690 | -6.8% | 0.01% | -14.3% |
| Q1 2019 | $477,000 | +5.1% | 13,620 | -0.4% | 0.01% | 0.0% |
| Q4 2018 | $454,000 | -47.8% | 13,680 | -20.7% | 0.01% | -36.4% |
| Q3 2018 | $869,000 | -19.2% | 17,260 | -4.0% | 0.02% | -24.1% |
| Q2 2018 | $1,076,000 | +36.4% | 17,980 | +4.4% | 0.03% | +45.0% |
| Q1 2018 | $789,000 | +4.9% | 17,220 | -8.7% | 0.02% | +11.1% |
| Q4 2017 | $752,000 | -12.4% | 18,870 | -12.0% | 0.02% | -18.2% |
| Q3 2017 | $858,000 | 0.0% | 21,450 | 0.0% | 0.02% | 0.0% |
| Q3 2016 | $858,000 | – | 21,450 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |